Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

You are correct it is not clear. It is clear the DMC will review the results after its interim analysis safety review. So about half of the patients will receive the 3 day treatment, whatever dose that is.

The other half could receive the 3 day or the 5 day course. It is possible sub groups or even individual patients could receive different treatment lengths based on their response to treatment ,but I think that would complicate the statistical analysis and make the"quadruple blinding" more complex.

I had the same thought that it was a compromise between IPIX and the FDA.

Hopefully the interim report will be more revealing.

Good luck,Farrell